Clinical Data ASCO: BMS hails “compelling” phase 3 celmod readout PharmaphorumBristol Myers Squibb has high hopes for its celmod drugs, and a phase 3 trial for mezigdomide in multiple myeloma at ASCO26 has delivered the goods.OncologyRead full story pharminent May 29, 2026 (Last updated: May 29, 2026) Pharmaphorum Bristol Myers Squibb has high hopes for its celmod drugs, and a phase 3 trial for mezigdomide in multiple myeloma at ASCO26 has delivered the goods. Oncology Read full story Post navigation Previous: Summit’s PD-1/VEGF to take center stage at ASCO, with wide impact for peersNext: Next Post Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026